Related references
Note: Only part of the references are listed.An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria
Sabine Altrichter et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2022)
FcεRI: A Master Regulator of Mast Cell Functions
Yuka Nagata et al.
CELLS (2022)
Determination of Biopsy Yield That Optimally Detects Eosinophilic Gastritis and/or Duodenitis in a Randomized Trial of Lirentelimab
Evan S. Dellon et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)
Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma (SOURCE): a randomised, placebo-controlled, phase 3 study
Michael E. Wechsler et al.
LANCET RESPIRATORY MEDICINE (2022)
Dupilumab prevents flares in adults with moderate to severe atopic dermatitis in a 52-week randomized controlled phase 3 trial
Joseph F. Merola et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2021)
Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines
Ioana Agache et al.
ALLERGY (2021)
Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY
Jonathan Corren et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Population pharmacokinetic analysis of dupilumab in adult and adolescent patients with asthma
Li Zhang et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2021)
Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
Tanya M. Laidlaw et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2021)
Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma
Leonard B. Bacharier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma
Michael E. Wechsler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
Andrew Menzies-Gow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Functionality and Performance of an Accessorized Pre-Filled Syringe and an Autoinjector for At-Home Administration of Tezepelumab in Patients with Severe, Uncontrolled Asthma
Sady Alpizar et al.
JOURNAL OF ASTHMA AND ALLERGY (2021)
Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years
Stephanie Korn et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma
Ioana Agache et al.
ALLERGY (2020)
Clinical significance of chemokine receptor antagonists
Miao Miao et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Dupilumab: Basic aspects and applications to allergic diseases
Kazuto Matsunaga et al.
ALLERGOLOGY INTERNATIONAL (2020)
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial
Florence Roufosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Benralizumab for Chronic Spontaneous Urticaria
Jonathan A. Bernstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Novel peptide nanoparticle-biased antagonist of CCR3 blocks eosinophil recruitment and airway hyperresponsiveness
Milica Grozdanovic et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Dupilumab improves symptoms, quality of life, and productivity in uncontrolled persistent asthma
Jonathan Corren et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2019)
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Mepolizumab improves small airway function in severe eosinophilic asthma
Claude S. Farah et al.
RESPIRATORY MEDICINE (2019)
Adverse events of benralizumab in moderate to severe eosinophilic asthma A meta-analysis
Wanshu Liu et al.
MEDICINE (2019)
Benralizumab for the Prevention of COPD Exacerbations
G. J. Criner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Biologics for Severe Asthma: Treatment-Specific Effects Are Important in Choosing a Specific Agent
James G. Krings et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2019)
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials
Claus Bachert et al.
LANCET (2019)
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
Karin Jonstam et al.
ALLERGY (2019)
Role of Biologics in Asthma
Mary Clare McGregor et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma
William W. Busse et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma
Sumita Khatri et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial
William W. Busse et al.
LANCET RESPIRATORY MEDICINE (2019)
Single-Use Autoinjector Functionality And Reliability For At-Home Administration Of Benralizumab For Patients With Severe Asthma: GRECO Trial Results
Gary T. Ferguson et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab
Giovanna E. Carpagnano et al.
JOURNAL OF ASTHMA AND ALLERGY (2019)
Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis
Yutaka Tomizawa et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2018)
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
M. Castro et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
Reynold A. Panettieri et al.
LANCET RESPIRATORY MEDICINE (2018)
Exacerbations of severe asthma in patients treated with mepolizumab
Rahul Shrimanker et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review
Arnaud Bourdin et al.
EUROPEAN RESPIRATORY JOURNAL (2018)
Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use
Diego Jose Maselli et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)
Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis
Daniel P. Henriksen et al.
EUROPEAN CLINICAL RESPIRATORY JOURNAL (2018)
A pilot randomised clinical trial of mepolizumab in COPD with eosinophilic bronchitis
Angira Dasgupta et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial
Claus Bachert et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tezepelumab in Adults with Uncontrolled Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial
Geoffrey L. Chupp et al.
LANCET RESPIRATORY MEDICINE (2017)
Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma
Kevin Murphy et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2017)
Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma Effects Across a Broad Range of Eosinophil Counts
Jonathan Corren et al.
CHEST (2016)
Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials
Zuo-Tao Zhao et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2016)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange
Luke F. Pennington et al.
NATURE COMMUNICATIONS (2016)
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania et al.
LANCET RESPIRATORY MEDICINE (2016)
IL-25 and IL-33 induce Type 2 inflammation in basophils from subjects with allergic asthma
Brittany M. Salter et al.
RESPIRATORY RESEARCH (2016)
A randomized trial of benralizumab, an antiinterleukin 5 receptor alpha monoclonal antibody, after acute asthma
Richard M. Nowak et al.
AMERICAN JOURNAL OF EMERGENCY MEDICINE (2015)
Chemokine receptors as therapeutic targets: Why aren't there more drugs?
Roberto Solari et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
Nicola A. Hanania et al.
THORAX (2015)
Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2015)
The therapeutic monoclonal antibody market
Dawn M. Ecker et al.
MABS (2015)
Profile of lebrikizumab and its potential in the treatment of asthma
Diego Jose Maselli et al.
JOURNAL OF ASTHMA AND ALLERGY (2015)
Type 2 inflammation in asthma - present in most, absent in many
John V. Fahy
NATURE REVIEWS IMMUNOLOGY (2015)
Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses
Gail M. Gauvreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study
Mario Castro et al.
LANCET RESPIRATORY MEDICINE (2014)
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Edward Piper et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes
Florence E. Roufosse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia
Michel Laviolette et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
R. D. May et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Monoclonal antibody therapeutics: history and future
Nicholas A. P. S. Buss et al.
CURRENT OPINION IN PHARMACOLOGY (2012)
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial
Ian D. Pavord et al.
LANCET (2012)
Reslizumab for Poorly Controlled, Eosinophilic Asthma A Randomized, Placebo-controlled Study
Mario Castro et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Allergen-induced expression of IL-25 and IL-25 receptor in atopic asthmatic airways and late-phase cutaneous responses
Chris J. Corrigan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2011)
Lebrikizumab Treatment in Adults with Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma
Chris J. Corrigan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial
A. Straumann et al.
GUT (2010)
Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor α antibody, in a phase I study of subjects with mild asthma
William W. Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
Roland Kolbeck et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
Marc Massanari et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Increased IL-33 expression by epithelial cells in bronchial asthma
David Prefontaine et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)
Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma
Pranabashis Haldar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma
Patrick Flood-Page et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Effect of omalizumab on patients with chronic urticaria
Sheldon L. Spector et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2007)
A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation
Patricia C. Fulkerson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
CC chemokine ligand 1 is released into the airways of atopic asthmatics
R. Montes-Vizuet et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines
J Schmitz et al.
IMMUNITY (2005)
Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354)
C Blanchard et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2005)
Anti-interieukin-5 (mepolizumab) therapy for hypereosinophilic syndromes
JK Garrett et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2004)
Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma - A pilot study 164/rccm.200206-5250C
JC Kips et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions
C Büttner et al.
EUROPEAN RESPIRATORY JOURNAL (2003)
The monocyte-derived chemokine is released in the bronchoalveolar lavage fluid of steady-state asthmatics
D Lezcano-Meza et al.
ALLERGY (2003)
Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human FcγRIII and antibody-dependent cellular toxicity
RL Shields et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)
H Milgrom et al.
PEDIATRICS (2001)
Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys
TK Hart et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2001)
Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response
MJ Leckie et al.
LANCET (2000)
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
E Ädelroth et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2000)
Share Paper
